文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

类癌综合征对胃肠胰神经内分泌肿瘤手术患者临床特征与结局的影响

Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
PubMed 文献 · Surgery · 2018-10-28

基于8家机构2000–2016年数据库,2182例接受手术的胃肠胰神经内分泌肿瘤患者中139例(6.4%)术前存在类癌综合征。类癌综合征患者更常见中肠原发、淋巴结转移和转移性疾病,但围术期类癌危象罕见,且类癌综合征并非无病生存或总生存的独立影响因素。

要点

  • 胃肠胰神经内分泌肿瘤手术患者中术前类癌综合征患病率为6.4%。
  • 类癌综合征与中肠原发、淋巴结转移及转移性疾病相关,但与肿瘤分化、分级或Ki67状态无关。
  • 类癌综合征不是无病生存或总生存的独立影响因素。

核心结论

  • 在接受手术切除的胃肠胰神经内分泌肿瘤患者中,术前类癌综合征患病率低,且在校正肿瘤负荷标志物后,类癌综合征并非无病生存或总生存的独立影响因素。

研究设计与样本

  • 回顾性多中心 collaborative 数据库研究,纳入2000–2016年间接受原发或转移性胃肠胰神经内分泌肿瘤切除的患者,共2182例,其中139例(6.4%)有术前类癌综合征。

主要发现

  • 类癌综合征患者中肠原发肿瘤比例更高(44.6% vs 21.4%,P < .001)。
  • 类癌综合征患者淋巴结转移比例更高(63.4% vs 44.3%,P < .001)。
  • 类癌综合征患者转移性疾病比例更高(62.8% vs 26.7%,P < .001)。
  • 肿瘤分化、分级或Ki67状态在有无类癌综合征患者间无差异。
  • 围术期类癌危象罕见(1.6% vs 0%,P < .01),术前类癌综合征与术后并发症无关(38.8% vs 45.5%,P = .129)。

临床怎么用

  • 对胃肠胰神经内分泌肿瘤手术患者,术前应识别类癌综合征,但类癌综合征本身不构成预后不良的独立因素。
  • 类癌综合征患者接受减瘤手术的症状改善率较低,治愈性意向切除者症状改善更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence, clinical characteristics, and long-term outcomes of patients with gastroenteropancreatic neuroendrocrine tumors and carcinoid syndrome undergoing operative resection have not been well characterized. METHODS: Patients undergoing resection of primary or metastatic gastroenteropancreatic neuroendrocrine tumors between 2000 and 2016 were identified from an 8-institution collaborative database. Clinicopathologic and postoperative characteristics as well as overall survival and disease-free survival were compared among patients with and without carcinoid syndrome. RESULTS: Among 2,182 patients who underwent resection, 139 (6.4%) had preoperative carcinoid syndrome. Patients with carcinoid syndrome were more likely to have midgut primary tumors (44.6% vs 21.4%, P < .001), lymph node metastasis (63.4% vs 44.3%, P < .001), and metastatic disease (62.8% vs 26.7%, P < .001). There was no difference in tumor differentiation, grade, or Ki67 status. Perioperative carcinoid crisis was rare (1.6% vs 0%, P < .01), and the presence of preoperative carcinoid syndrome was not associated with postoperative morbidity (38.8% vs 45.5%, P = .129). Substantial symptom improvement was reported in 59.5% of patients who underwent curative-intent resection, but occurred in only 22.7% who underwent debulking. Despite an association on univariate analysis (P = .04), carcinoid syndrome was not independently associated with disease-free survival after controlling for confounding factors (hazard ratio 0.97, 95% confidence interval 0.64-1.45). Preoperative carcinoid syndrome was not associated with overall survival on univariate or multivariate analysis. CONCLUSION: Among patients undergoing operative resection of gastroenteropancreatic neuroendrocrine tumors, the prevalence of preoperative carcinoid syndrome was low. Although operative intervention with resection or especially debulking in patients with carcinoid syndrome was disappointing and often failed to improve symptoms, after controlling for markers of tumor burden, carcinoid syndrome was not independently associated with worse disease-free survival or overall survival.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Kimbrough CW, Beal EW, Dillhoff ME, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery. 2018. PMID: 30377003. doi:10.1016/j.surg.2018.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。